OVER-TIME II Trial: Design and Rationale of a Multicenter Randomized Study Evaluating Antithrombotic Strategies in Patients with Acute Coronary Syndrome and Coronary Artery Ectasia

Clicks: 8
ID: 330706
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #76 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Coronary artery ectasia (CAE) is characterized by diffuse coronary dilatation and increased thrombotic risk. In patients with acute coronary syndrome (ACS) and CAE, the optimal antithrombotic strategy remains unclear. Previously, an exploratory trial suggested that the combination of antiplatelet monotherapy plus oral anticoagulation may reduce ischemic events without increasing bleeding risk compared to dual antiplatelet therapy (DAPT), although it was underpowered for definitive conclusions. Aim To evaluate the efficacy and safety of antiplatelet monotherapy plus direct oral anticoagulation compared with DAPT in patients with ACS and culprit-vessel CAE in a multicenter randomized setting. Methods OVER-TIME II is a multicenter, multinational, randomized, open-label clinical trial with 1:1 allocation comparing acetylsalicylic acid 100 mg plus clopidogrel 75 mg versus clopidogrel 75 mg plus rivaroxaban 15 mg daily. The study will include 326 patients with ACS and culprit-vessel CAE. Patients will be followed for 12 months. The co-primary efficacy endpoint is time to first occurrence of a composite of cardiovascular death, non-fatal myocardial infarction, or repeat revascularization. The co-primary safety endpoint is time to first occurrence of major or minor bleeding defined by the BARC criteria. Secondary endpoints include individual components of the primary outcomes. Exploratory analyses will include genomic and transcriptomic profiling through DNA and RNA sampling to identify molecular signatures associated with thrombotic risk, treatment response, and clinical outcomes. Conclusion OVER-TIME II is designed to provide robust multicenter randomized evidence regarding the efficacy and safety of an anticoagulation-based strategy in patients with ACS and CAE, with the potential to contribute to future clinical research and guideline development.
Reference Key
openalex_W7214967263 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Edith Adame-Avilés, Diego Araiza Garaygordobil, Lissette Haydee García-Mena, Marco Antonio Alcocer-Gamba, Ana Cristina Maldonado-May, Ricardo Álvarez-Santana, Nieto-Saucedo José Raúl, Alejandro Iván Rojas-Arriaga, Rodrigo Gopar‐Nieto, Daniel Sierra‐Lara, Luis Alfonso Marroquín Donday, Jesús Díaz-Marín, Leonor Jacobo‐Albavera, Alexandra Arias‐Mendoza, Mullasari Ajit Sankardas
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag161
URL
https://doi.org/10.1093/ehjopen/oeag161
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.